Bydureon BCise
exenatide extended-release — GLP-1 receptor agonist by AstraZeneca
GLP-1subcutaneous injectionOnce weeklyFDA Approved
Reviewed by Dr. Elena Vance, DOLast reviewed 5 sources cited
FDA-Approved Indications
- Type 2 diabetes mellitus (adjunct to diet and exercise)
Dosing
| Route | subcutaneous injection |
| Frequency | Once weekly |
| Starting Dose | 2 mg weekly |
| Maintenance | 2 mg weekly |
| Max Dose | 2 mg weekly |
| Titration | No titration required. 2 mg once weekly from start. |
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Nausea | 11% | 2/5 |
| Diarrhea | 9% | 2/5 |
| Injection site nodule | 10-17% | 2/5 |
| Headache | 8% | 1/5 |
| Vomiting | 4% | 3/5 |
| Constipation | 6% | 1/5 |
| Pancreatitis (rare) | <1% | 5/5 |
Cost
| List Price | $800-$950/month |
| With Insurance | $25-$100/month (varies by plan) |
| Savings Card | Limited savings programs available |
Pricing last updated 2026-04-14. Actual costs vary by pharmacy, insurance plan, and location.
Compare Bydureon BCise With
Boxed Warning
Thyroid C-cell tumors: In rodents, exenatide extended-release causes thyroid C-cell tumors. It is unknown whether exenatide causes thyroid C-cell tumors in humans.
Sources & References
FDA & Regulatory
Clinical Trial Records
Peer-Reviewed Literature
Manufacturer Information
Reference Entries
This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.